Table 3.
High Scoring Pairs of Interest from TF Model
| Target | High Scoring Indication in Clinical Pipeline (Phase*) | PubmedID | Related Approved Indication (Total Approved Indications) |
|---|---|---|---|
| ABCC8 | Glucose Intolerance (III) | 23903354 | Diabetes Mellitus (1) |
| ADRB1 | Cachexia (II) | 20426789 | Ischemia (13) |
| ADRB2 | Hypoglycemia (I) | 22013013 | Glaucoma (15) |
| ADRB2 | Myocardial Infarction (III) | 26692153 | Heart Failure (15) |
| AGTR1 | Hypercholesterolemia (III) | 12117739 | Hyperlipidemias (7) |
| CYP3A4 | Hepatitis C (II) | 20938912 | HIV Infections (1) |
| IL2 | Behcet Syndrome (II) | 26654556 | Graft Rejection (1) |
| IL6 | Waldenstrom Macroglobulinemia (I) | 26238488 | Giant Lymph Node Hyperplasia (1) |
| IL6 | Arthritis, Psoriatic (II) | 27789987 | Giant Lymph Node Hyperplasia (1) |
| OPRM1 | Schizophrenia (III) | 27397309 | Migraine Disorders (22) |
| RYR1 | Muscular Dystrophy, Duchenne (I) | 26793121 | Malignant Hyperthermia (1) |
| SERPINC1 | Hemophilia (II) | 27099538 | Blood Coagulation Disorders (16) |
| TNFSF11 | Hypercalcemia (II) | 27904108 | Osteoporosis (1) |
| VDR | Alopecia (I) | 27932380 | Keratosis (9) |
| VDR | Cachexia (I) | 22497530 | Chronic Kidney Failure (9) |
New indications of approved targets in clinical trials (Phase* as of May 27, 2016) that have the highest probability of eventual clinical success as measured by the tensor factorization model. The full list is available in the supplement. For illustrative purposes, we list a related indication approved for assets for each target